Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies.

The discovery of immune checkpoint inhibition (ICI) sparked a revolution in the era of targeted anticancer therapy. However, although monoclonal antibodies targeting the cytotoxic T-lymphocyte antigen-4 and programmed death-1 axes have improved survival in patients with advanced cancers, these immunotherapies are associated with a wide spectrum of dermatological immune-related adverse events (irAEs), ranging from mild to life-threatening. Several publications have addressed the clinical and histopathological classification of these skin-directed irAEs, their impact on anti-tumour immunity and survival, and the critical role of supportive oncological dermatology in their management. In this paper, we review the current understanding of the mechanistic drivers of immune-related skin toxicities with a focus on inflammatory, immunobullous and melanocyte/pigment-related reactions. We detail the specific immune-based mechanisms that may underlie different cutaneous reactions. We also discuss potential mechanisms as they relate to extracutaneous irAEs and the lessons learned from these, the potential overlap with cutaneous irAEs, techniques to study differences in immune-related vs. de novo skin reactions, and how treatment of these AEs impacts cancer treatment, patient quality of life and overall survival. An improved understanding of the mechanistic basis of cutaneous irAEs will allow clinicians to develop and use blood-based biomarkers that could help ultimately predict onset and/or severity of these irAEs, and to implement rational mechanistic-based treatment strategies that are targeted to the irAEs while potentially avoiding reducing the anti-tumour effect of ICIs.

I*DEA in the VA: Optimizing the Physician Workforce to Enhance Quality of Care.

Background: The demographic characteristics of veterans has changed significantly in recent years and continues to become more diverse. To enhance the quality of health care for the current community of enrolled veterans, it is critical that the physicians and health care leaders of the Veterans Health Administration (VHA) understand the changing demographics and health care needs of the veteran population. Observations: Studies have shown that increased inclusion, diversity, and equity among clinicians are associated with improved clinical outcomes. Diversity encompasses more than race and gender. Although the VHA workforce is relatively diverse, the same cannot be said about its leadership. The I*DEA (inclusion, diversity, equity, and access) Council is a new program that aims to eliminate gaps in VHA care and benefits to ensure that historically underserved veteran communities receive fair treatment. Conclusions: Optimizing I*DEA strategies-inclusion of diverse perspectives and ideas, equity of opportunities and accessibility within the VHA workforce-may help to enhance the quality of health care for veterans.

Inverted Appendix in a Patient With Weakness and Occult Bleeding.

Background: Appendiceal mucinous neoplasms (AMNs) are rare adenomatous primary tumors of the appendix. Although of low malignant potential, these neoplasms can cause serious potentially fatal complications such as bowel obstruction and pseudomyxoma peritonei, making prompt identification and removal of utmost importance. AMNs often present with nonspecific gastrointestinal symptoms or are asymptomatic and found incidentally. Case Presentation: A patient aged 72 years presented with generalized weakness and appeared on imaging to have acute appendicitis complicated by rupture. On colonoscopy, the patient was found to have an inverted appendix that after appendectomy was revealed to harbor a perforated low-grade AMN. Conclusions: Although AMNs are rare, physicians should still consider it when imaging suggests appendicitis. Having AMNs as part of the differential diagnosis is especially necessary in cases, such as this one, in which the patient has appendiceal inversion, is aged > 50 years, and has concurrent colorectal neoplasms.